Searched for
WHY MODERNA STOCK ROSE
Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trialModerna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, redu...- US stocks: US market regains ground as bond yields ease; healthcare stocks rallyMajor stock indexes recovered on Wednesday after a prior day's decline. Moderna shares surged significantly following positive cancer thera...
- US stocks today: US stocks end higher as investors turn to earnings seasonUS markets ended higher with the S&P 500 near record levels, driven by SK Hynix’s strong Nasdaq debut and renewed momentum in AI-linked chi...
- Dow Jones hits record intraday high before closing lower, S&P 500 and Nasdaq fall - here’s why US stock market started July in redUS stock market today July 1: US markets experienced a mixed trading day as the Dow Jones briefly hit a new intraday record before retreati...
- US stocks: US market ends lower as tech stocks weigh on sentimentWall Street ended lower on Friday, with AI chip stocks experiencing a significant downturn while Moderna and other healthcare companies sur...
- Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.
- US Stocks: Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhangModerna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possibl...
- Nvidia share price jumps big. Check top performing stocks at Wall Street todayU.S. Stock Market today: Most megacap and growth stocks rose on the day, with Nvidia gaining 2.6 per cent after the company said it had sig...
- Novavax soars 146% on $1.2 billion Sanofi vaccine licensing dealThe pact links two big players in the vaccine world that both missed out on the rush to develop and commercialize Covid shots quickly durin...
- Wall Street advances as CPI data eases concerns about interest rate hikesThe stock market expects the FED to loosen the tightrope after the CPI data came out lower than expected.
- Japanese shares drop as Moderna chief comments fan Omicron fearsThe broader Topix lost 1.03% to a three-month low of 1,928.35, slipping further below its closely-watched 200-day moving average.
- Wall Street rebounds after virus-related sell-off; Tesla up 5%Tesla's shares gained 5% after a report that chief Elon Musk urged employees to reduce the cost of vehicle deliveries.
- Moderna to join S&P 500, shares jump after hoursModerna shares rose 6% in extended trade after the announcement. The COVID-19 vaccine maker's stock has surged over 150% this year, elevati...
- Japanese shares gain tracking US futures; tech and pharma stocks boostThe Nikkei share average gained 0.67 per cent at 28.822.29, after declining 0.2 per cent earlier, while the broader Topix inched up 0.29 pe...
- Nikkei ends near 29.5 year high on vaccine, stimulus hopesThe Nikkei 225 index ended up 1.34 per cent at 26,787.54, near its highest level since April 1991, hit earlier in the session. The broader ...
- Nikkei hits 29-year high as vaccine optimism boosts risk appetiteThe Nikkei share average rose 0.42% to 26,014.62, its highest close since May 1991. The broader Topix added 0.15% to 1,734.39, after having...
- We can stop COVID-19: Moderna vaccine success gives world more hopeTogether with Pfizer Inc's vaccine, also shown to be more than 90% effective, and pending more safety data and regulatory review, the Unite...
- Wall Street rallies on vaccine bets, Goldman results"The Moderna news woke everybody up again that this is not going to last forever, and there is light at the end of the tunnel. That is why ...
- Gold prices firm on stimulus wave, doubts about possible vaccineUS gold futures rose 0.4 per cent to $1,751.80.
- Coronavirus vaccine from Moderna shows early signs of viral immune responseThe study was primarily designed to look at the safety of the shot and showed no major warning signs in a small phase 1 trial, the company ...
Load More
